Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

131results about How to "Effective infection" patented technology

Grass carp reovirus S11 gene eukaryotic expression recombinant plasmid preparation method and application thereof in serving as nucleic acid vaccine

The invention discloses a grass carp reovirus S11 gene eukaryotic expression recombinant plasmid preparation method and application thereof in serving as nucleic acid vaccine, and belongs to the technical field of gene engineering and molecular immunology. The preparation method disclosed by the invention is characterized by comprising the steps of extracting viral genome RNA, performing reverse transcription to convert the viral genome RNA into cDNA, amplifying a corresponding DNA sequence out, constructing the DNA sequence to pcDNA-3.1(+) plasmid, converting Escherichia coli DH5alpha, screening out positive clone bacteria containing recombinant plasmid, culturing a lot of the positive bacteria and extracting recombinant plasmid S11-pcDNA3.1 contained in the bacteria. The recombinant plasmid is utilized as nucleic acid vaccine to perform intramuscular injection on the grass carps, and the nucleic acid vaccine enters the muscle cells and expresses VP35 protein of the grass carp reovirus in the muscle cells; thus, fish body immune cell proliferation is stimulated, antiviral related gene expression is up regulated, fish bodies are stimulated to generate antiviral antibodies, and capability of grass carps in resisting grass carp reovirus infection is effectively improved; furthermore, the grass carp reovirus S11 gene eukaryotic expression recombinant plasmid can be used for preventing a grass carp hemorragic disease caused by the grass carp reovirus in aquaculture.
Owner:HENAN NORMAL UNIV

Pharmaceutical composition for preventing and treating COVID-19 and preparation method of pharmaceutical composition

The invention belongs to the technical field of medicines. The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for preventing and treating COVID-19 (diseases caused by novel coronaviruses) and a preparation method thereof. The pharmaceutical composition comprises active ingredients of mycobacterium vaccae for injection and salbutamol sulfate, and the weight ratio of the mycobacterium vaccae for injection to the salbutamol sulfate is 1: (50-200). The medicine prepared from the medicine composition can adopt an aerosol inhalation treatment mode, and through short-term aerosol inhalation, the compliance of a patient can be improved by providing the medicine with a specific purpose for the patient, so that the patient can take the medicine conveniently, and the medical cost is reduced. The pharmaceutical composition for preventing and treating COVID-19 disclosed by the invention has the advantages that the COVID-19 can be effectively prevented and treated; severe or critical symptoms of patients are relieved, nucleic acid negative conversion time is shortened by about 4 days averagely, treatment time is correspondingly shortened, other respiratory virus infections can be prevented and treated nonspecifically, and a new way and scheme are provided for clinical prevention and treatment of COVID-19 and respiratory virus infections.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV

Genetic engineering expression and preparation methods of cecropin LL-37 and application thereof

The invention relates to genetic engineering expression and preparation methods of cecropin LL-37 and application thereof. The preparation method comprises the steps of synthesizing a DNA (Deoxyribonucleic Acid) sequence coding the cecropin LL-37, and connecting the DNA sequence to a suitable expression vector for expression and purification, wherein the DNA sequence coding the cecropin LL-37 adopts Escherichia coli preferred codons, and the LL-37 expressed in an Escherichia coli fusion and expression system accounts for about 20% of the total protein of a thallus; and cutting off the purified fusion protein by using cyanogen bromide so as to obtain the target polypeptide LL-37, and obtaining LL-37 powder with the purity higher than 90% through HPLC (High-Performance Liquid Chromatography). The LL-37 of low concentration can play a significant bactericidal effect in the aspect of human preparations for external use, serves as a drug for external use and is applied to the treatment of diseases, such as skin infection. The methods have the advantages that the cecropin LL-37 is expressed and prepared in the form of fusion protein, the process is simple, and the yield of fermentation liquor per cubic liter can reach 20 mg, so that the methods have significance in industrial batch production.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products